Precision Medicine in Oncology®

Physicians are carefully evaluating potential partnership and referral deals to ensure that whatever they do is perceived as aligned with delivering better, more efficient care.

Dan J. Raz, MD, MAS, co-director, Lung Cancer and Thoracic Oncology Program, assistant professor, Division of Thoracic Surgery, Department of Surgery, City of Hope, discusses the subsets of the ALCHEMIST trial.

The FDA’s recent approvals of novel anti-PARP agents as maintenance therapy for patients with previously treated advanced ovarian cancer highlight an issue that has received inadequate attention in the peer-reviewed oncology literature.

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the potential of existing targeted therapy coupled with immunotherapy to improve overall survival (OS) in patients with kidney cancer.